The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions

Stopped early · Phase 3

Conditions studied: Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease, Peripheral Arterial Occlusive Disease

In brief

This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.

Key facts

Study ID

NCT04007055

Run by

Marissa Jarosinski

People needed

31

Starts

2019-08-09

Expected to finish

2024-03-28

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Peripheral arterial disease
• Planned angioplasty or stenting of superficial femoral artery or popliteal artery.

You may not qualify if…

• Patients treated on an emergency basis
• Planned intervention on prior site of open surgical intervention (autogenous or autologous bypass, endarterectomy, or patch angioplasty)
• Planned intervention at site exclusive of superficial femoral artery or popliteal artery
• Planned re-stenting at site of prior stent placement
• Planned re-angioplasty at site of prior angioplasty
• Known inability to tolerate antiplatelet regimen before enrollment
• Patients who plan on receiving follow up care outside the University of Pittsburgh Medical Center
• Current use of prasugrel or ticlopidine
• Current use of oral anticoagulation medication
• Pregnant patients

Where it is running

• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.